Tag: Cell Therapy

Sangamo Therapeutics Granted MHRA Authorisation to Conduct Trial of Novel Type of Cell Therapy

Sangamo Therapeutics has been granted authorisation from the UK’s Medicines Healthcare Products Regulatory Agency (MHRA) to conduct the first-in-human clinical trial of a novel type of cell therapy - ...

Editas Medicine Announced Amended Collaboration with Celgene Corporation

celgene
Editas Medicine, Inc., a leading genome editing company, announced an amended collaboration with Celgene Corporation under which the parties may research, develop, and commercialize autologous and all...

Genentech Exercised Final Option for Exclusive Target Under Agreement with Affimed

Genentech, a member of the Roche Group, has exercised its final option for an exclusive target under a collaboration agreement with Affimed N.V. to develop and commercialize novel NK cell engager-...

Adaptimmune and Cryoport Announced Agreement to Ensure Transport of Cell Therapies

cells
Adaptimmune Therapeutics and Cryoport announced a three-year agreement to ensure fully monitored transport of Adaptimmune’s cell therapies. Optimizing manufacturing and supply operations and reduci...

GSK Announced Five-Year Collaboration with Lyell Immunopharma

gsk
GlaxoSmithKline plc announced a five-year collaboration with Lyell Immunopharma, a San Francisco biotechnology company, to develop new technologies to improve cell therapies for cancer patients. The c...

First Australian Company to Gain T-Cell GMP Manufacturing Licence

The licence allows for the collection, manufacturing, testing, storage and release for the supply of any commercial T-Cell product. The Therapeutic Goods Administration (TGA) of Australia has grant...

Astellas and RIKEN Entered Worldwide Licensing Agreement for Cell Therapy R&D

astellas
RIKEN and Astellas Pharma Inc. announced that they have entered into a worldwide licensing agreement for the research, development and commercialization of cell therapy formulations applying RIKEN’s a...

Immatics Biotechnologies and Celgene Signed Collaboration Deal Worth $1.59bn

Immatics Biotechnologies and Celgene have signed a collaboration and option deal worth up to $1.59bn (£1.3bn) to develop novel adoptive cell therapies against multiple cancers. Based in Germany...

£267,000 Grant for Cell Therapy Stabilisation Technologies

Atelerix Consortium awarded £267,000 Innovate UK Grant for collaboration with the Cell and Gene Therapy Catapult and Rexgenero on cell therapy stabilisation technologies. Rexgenero, a regenerative me...

FDA Granted Fast Track Designation for Investigational Cell Therapy

stem-cell
DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the ...

Health Canada Approved Next-Generation AXP® II System for Cord Blood Processing

ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing, announced that it has received Health Canada approval of its ...

Tessa Establish Landmark $120m Joint Venture to Develop Innovative Cell Therapies for Cancer

cells
Tessa Therapeutics (Tessa), a clinical-stage cell therapy company focused on the development of autologous and allogeneic therapies to treat cancer, announced that it will establish a joint venture wi...

ElevateBio Gets $150M to Launch Cell and Gene Therapy Incubator

gene-therapy
ElevateBio, a Cambridge-based biotechnology holding company, today announced operations to create and build a broad portfolio of cell and gene therapy companies through partnerships with leading acade...

Kite to Expand Cell Therapy Production Capabilities

Kite, a Gilead Company, today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer. The 20-acre site will significantly...

ReNeuron Partners with Fosun Pharma in China

ReNeuron licenses rights to its CTX and hRPC cell therapy programmes to Fosun Pharma for Chinese market. ReNeuron to receive upfront, near term and estimated success-based milestone payments of $104.8...

First Patient Infused with CTX001 for TDT Treatment

CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated reviewed recent progress in the clinical development programs for CTX001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoie...